Eris Lifesciences Limited has informed the Exchange regarding 'INSPECTION OF SWISS PARENTERALS UNITS 1 AND 2 BY HALMED, CROATIA'.
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
HALMED, Croatia's drug regulatory agency, inspected Swiss Parenterals Ltd.'s manufacturing units in Ahmedabad from March 9-13, 2026. The inspection covered Unit 1 (general liquid and dry powder injectables) and Unit 2 (betalactam dry powder injectables). The company received non-compliance observations, which it describes as procedural in nature related to GMP compliance under EU Directive 2017/1572. Eris plans to submit corrective and preventive actions (CAPAs) and request a follow-on inspection to reinstate approvals. The company states business impact is minimal, though there will be delays in commercializing its EU CDMO product pipeline.
The regulatory scrutiny is a setback for the company's EU market expansion plans, though the company downplays the impact on existing business. Shareholders should monitor whether the follow-on inspection resolves the issues without further delays.